SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Furlow Brenda S.

(Last) (First) (Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MN 55413

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP - General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 6,124 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $108.49 (2) 08/07/2022 Common Stock 921 921 D
Stock Options (Right to Buy) $106.59 (2) 08/18/2023 Common Stock 3,538 3,538 D
Stock Options (Right to Buy) $125.05 (2) 08/09/2024 Common Stock 9,503 9,503 D
Stock Options (Right to Buy) $125.05 (3) 08/09/2024 Common Stock 12,670 12,670 D
Restricted Stock Units (1) (4) (4) Common Stock 1,374 1,374 D
Stock Options (Right to Buy) $177.32 (4) 08/08/2025 Common Stock 7,339 7,339 D
Stock Options (Right to Buy) $177.32 (5) 08/08/2025 Common Stock 9,786 9,786 D
Restricted Stock Units (1) (6) (6) Common Stock 1,969 1,969 D
Stock Options (Right to Buy) $190.41 (6) 08/07/2026 Common Stock 9,968 9,968 D
Stock Options (Right to Buy) $190.41 (7) 08/07/2026 Common Stock 13,290 13,290 D
Restricted Stock Units (1) (8) (8) Common Stock 1,679 1,679 D
Stock Options (Right to Buy) $267.87 (8) 08/05/2027 Common Stock 7,492 7,492 D
Stock Options (Right to Buy) $267.87 (9) 08/05/2027 Common Stock 9,990 9,990 D
Stock Options (Right to Buy) $267.87 (10) 08/05/2027 Common Stock 8,325 8,325 D
Stock Options (Right to Buy) $267.87 (11) 08/05/2027 Common Stock 8,325 8,325 D
Stock Options (Right to Buy) $372.44 03/01/2021 A 10,997 08/31/2022 03/01/2028 Common Stock 10,997 $0 10,997 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
2. Fully exercisable.
3. Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
4. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
6. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
8. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
9. Options to purchase 2,498 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 2,497 shares vest on each of 8/5/2023 and 8/5/2024.
10. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021
11. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
Remarks:
/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed. 03/03/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.